Patients TMS works. Why do fewer than 1% of eligible patients get it? A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.
R&D Removing barriers in treatment-resistant depression pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.
Patients Breaking Bipolar I disorder stigma in the Hispanic community For many Hispanic patients and families, that is where the gap between need and treatment can begin.
Patients Decline in overdose deaths ≠ The end of the opioid crisis Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s commitment to
News Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.
Patients In schizophrenia care, even the support system needs support After a schizophrenia diagnosis, families must learn how to navigate treatment, respond to symptoms, and communicate effectively.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.